Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 19
Encontrada(s) 1 página(s)

Repisalud
Publicación Artículo de revisión (ReviewArticle)

Evaluation of the recombinant protein -TSP-2 for the serological diagnosis of imported urogenital schistosomiasis and comparison with commercially available tests

  • Luzón-García, María Pilar
  • Navarro, Laura
  • Rodríguez, Esther
  • Soriano-Pérez, Manuel Jesús
  • Vázquez-Villegas, José
  • Cabeza-Barrera, María Isabel
  • Loukas, Alex
  • Castillo-Fernández, Nerea
  • Perteguer-Prieto, Maria Jesus
  • Sotillo, Javier
  • Salas-Coronas, Joaquin
Different agencies have emphasized the need to evaluate current serological methods for screening patients with suspected urogenital schistosomiasis. However, there is still a lack of evidence regarding the most appropriate methods for this purpose. Here we assessed the diagnostic efficacy of a newly developed serological technique that utilizes the recombinant protein -TSP-2, applied to the urine and serum of migrants suspected of having urogenital schistosomiasis. The sensitivity, specificity, positive and negative predictive values of an in-house enzyme-linked immunosorbent assay (ELISA) using the recombinant protein -TSP-2 were analysed and compared with other commercial serological methods. Due to the limitations of microscopy as a perfect reference method, a latent class analysis (LCA) and composite reference standard (CRS) approach was used to determine the sensitivity and specificity of each test. According to the LCA model, the commercial tests NovaLisa and immunochromatography test (ICT) immunoglobulin G–immunoglobulin M (IgG–IgM) presented the highest sensitivity (100%), whereas the -TSP-2 serum ELISA test had 79.2%. The -TSP-2 urine and serum ELISA tests had the highest specificities among the serological methods (87.5 and 75%, respectively). CRS modelling showed that the ICT IgG–IgM, NovaLisa and -TSP-2 serum tests led in sensitivity at 97.1, 88.6 and 71.4%, respectively, with all tests except that the ICT IgG–IgM test having a specificity >90%. -TSP-2 has been validated as a screening tool for patients suspected of having urogenital schistosomiasis. Although commercial serological tests have shown higher sensitivities, -TSP-2 could be valuable for confirming results from tests with lower specificity. Nevertheless, further studies with larger patient cohorts are necessary to fully verify its potential.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Mitochondrial–nuclear p53 trafficking controls neuronal susceptibility in stroke

  • Almeida, Angeles
  • Sánchez Morán, Irene
  • Rodríguez González, Cristina
Stroke is a major cause of death and long-term disability in the adult. Neuronal apoptosis plays an essential role in the pathophysiology of ischemic brain damage and impaired functional recovery after stroke. The tumor suppressor protein p53 regulates key cellular processes, including cell cycle arrest, DNA repair, senescence, and apoptosis. Under cellular stress conditions, p53 undergoes post-translational modifications, which control protein localization, stability, and proapoptotic activity. After stroke, p53 rapidly accumulates in the ischemic brain, where it activates neuronal apoptosis through both transcriptional-dependent and -independent programs. Over the last years, subcellular localization of p53 has emerged as an important regulator of ischemia-induced neuronal apoptosis. Upon an ischemic insult, p53 rapidly translocates to the mitochondria and interacts with B-cell lymphoma-2 family proteins, which activate the mitochondrial apoptotic program, with higher efficacy than through its activity as a transcription factor. Moreover, the identification of a human single nucleotide polymorphism at codon 72 of the Tp53 gene that controls p53 mitochondrial localization and cell susceptibility to apoptosis supports the important role of the p53 mitochondrial program in neuronal survival and functional recovery after stroke. In this article, we review the relevance of mitochondrial and nuclear localization of p53 on neuronal susceptibility to cerebral ischemia and its impact on functional outcome of stroke patients., Consejería de Educación, Junta de Castilla y León, Grant/Award Numbers: CLU-2017-03, CSI151P20; EU Horizon 2020Research and Innovation Programme,Grant/Award Number: GA 686009;Ministerio de Ciencia e Innovación,Grant/Award Number:SAF2017-90794-REDT to AA; Junta deCastilla y León; Horizon 2020; EuropeanUnion; European Regional DevelopmentFund; Instituto de Salud Carlos III, Grant/Award Numbers: PI18/00265,RD16/0019/0018
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

A summary on the genetics of Systemic Lupus erythematosus, rheumatoid arthritis, systemic sclerosis, and Sjögren’s syndrome

  • Ortiz-Fernández, Lourdes
  • Martín, Javier
  • Alarcón-Riquelme, M. E.
Systemic lupus erythematosus, systemic sclerosis, rheumatoid arthritis, and Sjögren’s syndrome are four major autoimmune rheumatic diseases characterized by the presence of autoantibodies, caused by a dysregulation of the immune system that leads to a wide variety of clinical manifestations. These conditions present complex etiologies strongly influenced by multiple environmental and genetic factors. The human leukocyte antigen (HLA) region was the first locus identified to be associated and still represents the strongest susceptibility factor for each of these conditions, particularly the HLA class II genes, including DQA1, DQB1, and DRB1, but class I genes have also been associated. Over the last two decades, the genetic component of these disorders has been extensively investigated and hundreds of non-HLA risk genetic variants have been uncovered. Furthermore, it is widely accepted that autoimmune rheumatic diseases share molecular disease pathways, such as the interferon (IFN) type I pathways, which are reflected in a common genetic background. Some examples of well-known pleiotropic loci for autoimmune rheumatic diseases are the HLA region, DNASEL13, TNIP1, and IRF5, among others. The identification of the causal molecular mechanisms behind the genetic associations is still a challenge. However, recent advances have been achieved through mouse models and functional studies of the loci. Here, we provide an updated overview of the genetic architecture underlying these four autoimmune rheumatic diseases, with a special focus on the HLA region., This work was supported by the Spanish Ministry of Science and Innovation RTI2018-101332-B-100 to JM and PID2020-113776 Gb-I00 to MEAR), Red de Investigación en Inflamación y Enfermedades Reumáticas (RIER) from Instituto de Salud Carlos III (RD16/0012/0013 to JM), the Consejería de Salud y Familias (PE-0297–2019 to MEAR), and the Consejería de Transformación económica, industria, conocimiento y universidades (PY20-00473 to MEAR). LOF was funded by the Spanish Ministry of Science and Innovation through the Juan de la Cierva Incorporacion program (ref. IJC2019-040746-I)
Dipòsit Digital de Documents de la UAB
Publicación Artículo de revisión (ReviewArticle)

Deciphering the iron side of stroke, Neurodegeneration at the crossroads between iron dyshomeostasis, excitotoxicity, and ferroptosis

  • Gregorio-Rocasolano Barbany, Núria de|||0000-0001-5248-7525
  • Martí-Sistac, O.
  • Gasull Dalmau, Teresa|||0000-0002-9321-1741
In general, iron represents a double-edged sword in metabolism in most tissues, especially in the brain. Although the high metabolic demands of brain cells require iron as a redox-active metal for ATP-producing enzymes, the brain is highly vulnerable to the devastating consequences of excessive iron-induced oxidative stress and, as recently found, to ferroptosis as well. The blood-brain barrier (BBB) protects the brain from fluctuations in systemic iron. Under pathological conditions, especially in acute brain pathologies such as stroke, the BBB is disrupted, and iron pools from the blood gain sudden access to the brain parenchyma, which is crucial in mediating stroke-induced neurodegeneration. Each brain cell type reacts with changes in their expression of proteins involved in iron uptake, efflux, storage, and mobilization to preserve its internal iron homeostasis, with specific organelles such as mitochondria showing specialized responses. However, during ischemia, neurons are challenged with excess extracellular glutamate in the presence of high levels of extracellular iron; this causes glutamate receptor overactivation that boosts neuronal iron uptake and a subsequent overproduction of membrane peroxides. This glutamate-driven neuronal death can be attenuated by iron-chelating compounds or free radical scavenger molecules. Moreover, vascular wall rupture in hemorrhagic stroke results in the accumulation and lysis of iron-rich red blood cells at the brain parenchyma and the subsequent presence of hemoglobin and heme iron at the extracellular milieu, thereby contributing to iron-induced lipid peroxidation and cell death. This review summarizes recent progresses made in understanding the ferroptosis component underlying both ischemic and hemorrhagic stroke subtypes.
Dipòsit Digital de Documents de la UAB
Publicación Artículo de revisión (ReviewArticle)

Therapeutic Use of LSD in Psychiatry, A Systematic Review of Randomized-Controlled Clinical Trials

  • Fuentes, Juan José
  • Fonseca, Francina|||0000-0002-0779-6545
  • Elices, M.|||0000-0002-7034-4242
  • Farré Albaladejo, Magí|||0000-0001-8338-7543
  • Torrens, Marta
Lysergic acid diethylamide (LSD) was studied from the 1950s to the 1970s to evaluate behavioral and personality changes, as well as remission of psychiatric symptoms in various disorders. LSD was used in the treatment of anxiety, depression, psychosomatic diseases and addiction. However, most of the studies were not performed under contemporary standards, and it has taken several decades for a resurgence of interest in LSD research and its therapeutic potential for psychiatry. The aim of this review is to identify controlled and randomized clinical trials that assess the potential use of LSD in psychiatry. PRISMA guidelines for systematic review were followed. A literature search of PubMed and Psychedelic bibliography from Multidisciplinary Association for Psychedelic Studies (MAPS) databases was performed as well as a manual search of references from evaluated studies. Only randomized-controlled clinical trials were included. Study quality was systematically calculated by using the Cochrane Collaboration Tool for assessing risk of bias. A final selection of 11 articles was made after considering inclusion and exclusion criteria. LSD was administered to 567 patients in a dose ranging from 20 to 800 mcg. Despite the design heterogeneity of clinical trials, positive results were observed, thus revealing the therapeutic potential of LSD to reduce psychiatric symptomatology, mainly in alcoholism. The vast majority of authors describe significant and positive short-term changes in patients, despite the fact that in some studies an important homogenization was observed between the LSD treatment group and control group at long-term follow-up. Multiple variables regarding LSD treatment therapeutic approach and quality of experience were revealed and related to therapeutic outcomes. LSD is revealed as a potential therapeutic agent in psychiatry; the evidence to date is strongest for the use of LSD in the treatment of alcoholism. Despite the difficulty of designing proper double blind clinical trials with this substance, new studies that conform to modern standards are necessary in order to strengthen our knowledge on its use and open new doors in the future.
Dipòsit Digital de Documents de la UAB
Publicación Artículo de revisión (ReviewArticle)

Recent advances in the clinical management of autosomal dominant polycystic kidney disease

  • Torra Balcells, Roser|||0000-0001-8714-2332
Autosomal dominant polycystic kidney disease (ADPKD) is a genetic systemic disorder causing the development of renal and hepatic cysts and decline in renal function. It affects around 1 in 1,000 live births. Early hypertension and progressive renal failure due to massive enlargement of cysts and fibrosis are hallmarks of the disease. This article reviews recent advances in ADPKD and focuses mainly on diagnosis, management, and prediction of the course of the disease.
Dipòsit Digital de Documents de la UAB
Publicación Artículo de revisión (ReviewArticle)

Schwann Cell Role in Selectivity of Nerve Regeneration

  • Bolívar Martín, Sara|||0000-0003-2966-6845
  • Navarro, Xavier|||0000-0001-9849-902X
  • Udina i Bonet, Esther|||0000-0003-1954-8562
Peripheral nerve injuries result in the loss of the motor, sensory and autonomic functions of the denervated segments of the body. Neurons can regenerate after peripheral axotomy, but inaccuracy in reinnervation causes a permanent loss of function that impairs complete recovery. Thus, understanding how regenerating axons respond to their environment and direct their growth is essential to improve the functional outcome of patients with nerve lesions. Schwann cells (SCs) play a crucial role in the regeneration process, but little is known about their contribution to specific reinnervation. Here, we review the mechanisms by which SCs can differentially influence the regeneration of motor and sensory axons. Mature SCs express modality-specific phenotypes that have been associated with the promotion of selective regeneration. These include molecular markers, such as L2/HNK-1 carbohydrate, which is differentially expressed in motor and sensory SCs, or the neurotrophic profile after denervation, which differs remarkably between SC modalities. Other important factors include several molecules implicated in axon-SC interaction. This cell-cell communication through adhesion (e.g., polysialic acid) and inhibitory molecules (e.g., MAG) contributes to guiding growing axons to their targets. As many of these factors can be modulated, further research will allow the design of new strategies to improve functional recovery after peripheral nerve injuries.
Dipòsit Digital de Documents de la UAB
Publicación Artículo de revisión (ReviewArticle)

Relevance of Porcine Stroke Models to Bridge the Gap from Pre-Clinical Findings to Clinical Implementation

  • Melià Sorolla, Marc|||0000-0002-4425-1077
  • Gregorio-Rocasolano Barbany, Núria de|||0000-0001-5248-7525
  • Rodríguez-Esparragoza, Luis
  • Dávalos, Antoni|||0000-0003-2949-5679
  • Martí-Sistac, Octavi
  • Gasull Dalmau, Teresa|||0000-0002-9321-1741
  • Castaño Duque, Carlos|||0000-0001-9165-340X
In the search of animal stroke models providing translational advantages for biomedical research, pigs are large mammals with interesting brain characteristics and wide social acceptance. Compared to rodents, pigs have human-like highly gyrencephalic brains. In addition, increasingly through phylogeny, animals have more sophisticated white matter connectivity; thus, ratios of white-to-gray matter in humans and pigs are higher than in rodents. Swine models provide the opportunity to study the effect of stroke with emphasis on white matter damage and neuroanatomical changes in connectivity, and their pathophysiological correlate. In addition, the subarachnoid space surrounding the swine brain resembles that of humans. This allows the accumulation of blood and clots in subarachnoid hemorrhage models mimicking the clinical condition. The clot accumulation has been reported to mediate pathological mechanisms known to contribute to infarct progression and final damage in stroke patients. Importantly, swine allows trustworthy tracking of brain damage evolution using the same non-invasive multimodal imaging sequences used in the clinical practice. Moreover, several models of comorbidities and pathologies usually found in stroke patients have recently been established in swine. We review here ischemic and hemorrhagic stroke models reported so far in pigs. The advantages and limitations of each model are also discussed.
Dipòsit Digital de Documents de la UAB
Publicación Artículo de revisión (ReviewArticle)

Transitioning From Preclinical Evidence to Advanced Therapy Medicinal Product, A Spanish Experience

  • Gastelurrutia, Paloma|||0000-0001-6974-9210
  • Prat-Vidal, Cristina|||0000-0002-5621-1101
  • Vives Armengol, Joaquim|||0000-0001-9719-5235
  • Coll-Bonet, Ruth|||0000-0003-0174-379X
  • Bayés-Genís, Antoni|||0000-0002-3044-197X
  • Gálvez-Montón, Carolina|||0000-0003-2254-9371
A systematic and ordered product development program, in compliance with current quality and regulatory standards, increases the likelihood of yielding a successful advanced therapy medicinal product (ATMP) for clinical use as safe and effective therapy. As this is a novel field, little accurate information is available regarding the steps to be followed, and the information to be produced to support the development and use of an ATMP. Notably, successful clinical translation can be somewhat cumbersome for academic researchers. In this article, we have provided a summary of the available information, supported by our experience in Spain throughout the development of an ATMP for myocardial infarction, from the pre-clinical stage to phase I clinical trial approval.
Dipòsit Digital de Documents de la UAB
Publicación Artículo de revisión (ReviewArticle)

The Evolving Microbiome from Pregnancy to Early Infancy, A Comprehensive Review

  • Mesa, María Dolores|||0000-0003-4079-6464
  • Loureiro, Begoña|||0000-0001-6065-1364
  • Iglesia, Iris|||0000-0002-2219-3646
  • Fernandez Gonzalez, Sergi
  • Llurba, Elisa|||0000-0003-4048-6407
  • Garcia-Algar, Oscar|||0000-0001-5708-4362
  • Solana, María José|||0000-0001-6083-2528
  • Cabero Perez, Mª Jesús
  • Sainz, Talia|||0000-0002-5301-0945
  • Martinez, Leopoldo
  • Escuder-Vieco, Diana
  • Parra-Llorca, Anna
  • Sánchez-Campillo, María|||0000-0002-7177-8341
  • Rodriguez Martinez, Gerardo
  • Gómez-Roig, María Dolores|||0000-0003-2329-1851
  • Perez Gruz, Myriam
  • Andreu-Fernandez, Vicente|||0000-0001-7183-8706
  • Clotet, Jordi
  • Sailer, Sebastian
  • Iglesias-Platas, Isabel
  • López Herce, Jesús|||0000-0001-6105-9178
  • Aras, Rosa
  • Pallás-Alonso, Carmen|||0000-0001-9710-8162
  • Saenz de Pipaon, Miguel|||0000-0002-4793-1561
  • Vento Torres, Máximo|||0000-0003-0061-4742
  • Gormaz, María
  • Larqué Daza, Elvira
  • Calvo, Cristina|||0000-0002-6503-3423
  • Cabañas, Fernando
Pregnancy induces a number of immunological, hormonal, and metabolic changes that are necessary for the mother to adapt her body to this new physiological situation. The microbiome of the mother, the placenta and the fetus influence the fetus growth and undoubtedly plays a major role in the adequate development of the newborn infant. Hence, the microbiome modulates the inflammatory mechanisms related to physiological and pathological processes that are involved in the perinatal progress through different mechanisms. The present review summarizes the actual knowledge related to physiological changes in the microbiota occurring in the mother, the fetus, and the child, both during neonatal period and beyond. In addition, we approach some specific pathological situations during the perinatal periods, as well as the influence of the type of delivery and feeding. his research was funded by the PN I+D+I 2008-2011 (Spain), ISCIII- Sub-Directorate General for Research Assessment and Promotion and the European Regional Development Fund (ERDF), RETICS Maternal and Child Health and Development Network, SAMID Network, Ref.
Dipòsit Digital de Documents de la UAB
Publicación Artículo de revisión (ReviewArticle)

Post-Genomic Methodologies and Preclinical Animal Models, Chances for the Translation of Cardioprotection to the Clinic

  • Badimon, Lina|||0000-0002-9162-2459
  • Mendieta, Guiomar|||0000-0001-6652-9036
  • Ben-Aicha Gonzalez, Soumaya|||0000-0001-5572-5883
  • Vilahur, Gemma|||0000-0002-2828-8873
Although many cardioprotective strategies have demonstrated benefits in animal models of myocardial infarction, they have failed to demonstrate cardioprotection in the clinical setting highlighting that new therapeutic target and treatment strategies aimed at reducing infarct size are urgently needed. Completion of the Human Genome Project in 2001 fostered the post-genomic research era with the consequent development of high-throughput "omics" platforms including transcriptomics, proteomics, and metabolomics. Implementation of these holistic approaches within the field of cardioprotection has enlarged our understanding of ischemia/reperfusion injury with each approach capturing a different angle of the global picture of the disease. It has also contributed to identify potential prognostic/diagnostic biomarkers and discover novel molecular therapeutic targets. In this latter regard, "omic" data analysis in the setting of ischemic conditioning has allowed depicting potential therapeutic candidates, including non-coding RNAs and molecular chaperones, amenable to pharmacological development. Such discoveries must be tested and validated in a relevant and reliable myocardial infarction animal model before moving towards the clinical setting. Moreover, efforts should also focus on integrating all "omic" datasets rather than working exclusively on a single "omic" approach. In the following manuscript, we will discuss the power of implementing "omic" approaches in preclinical animal models to identify novel molecular targets for cardioprotection of interest for drug development.
Dipòsit Digital de Documents de la UAB
Publicación Artículo de revisión (ReviewArticle)

Adapting Cord Blood Collection and Banking Standard Operating Procedures for HLA-Homozygous Induced Pluripotent Stem Cells Production and Banking for Clinical Application

  • Álvarez Palomo, Belén|||0000-0002-3894-044X
  • Vives Armengol, Joaquim|||0000-0001-9719-5235
  • Casaroli-Marano, Ricardo Pedro|||0000-0003-1812-9323
  • G. Gómez, Susana
  • Rodríguez Gómez, Luciano
  • Edel, Michael J.|||0000-0002-5619-8680
  • Querol, Sergi|||0000-0002-1105-8633
In this article, we will discuss the main aspects to be considered to define standard operation procedures (SOPs) for the creation of an induced pluripotent stem cell (iPSC) bank using cord blood (CB)-or similar cell type-bank guidelines for clinical aims. To do this, we adapt the pre-existing SOP for CB banking that can be complementary for iPSCs. Some aspects of iPSC manufacturing and the particular nature of these cells call for special attention, such as the potential multiple applications of the cells, proper explanation to the donor for consent of use, the genomic stability and the risk of genetic privacy disclosure. Some aspects of the iPSC SOP are solidly established by CB banking procedures, other procedures have good consensus in the scientific and medical community, while others still need to be further debated and settled. Given the international sharing vocation of iPSC banking, there is an urgent need by scientists, clinicians and regulators internationally to harmonize standards and allow future sample interchange between many iPSC bank initiatives that are springing up worldwide.
Dipòsit Digital de Documents de la UAB
Publicación Artículo de revisión (ReviewArticle)

C-Reactive Protein as a Therapeutic Target in Age-Related Macular Degeneration

  • Molins, Blanca|||0000-0003-0941-9134
  • Romero-Vázquez, Sara|||0000-0002-2053-7230
  • Fuentes-Prior, Pablo|||0000-0002-6618-3204
  • Adan Civera, Alfredo|||0000-0002-0849-8814
  • Dick, Andrew D.
Age-related macular degeneration (AMD), a retinal degenerative disease, is the leading cause of central vision loss among the elderly population in developed countries and an increasing global burden. The major risk is aging, compounded by other environmental factors and association with genetic variants for risk of progression. Although the etiology of AMD is not yet clearly understood, several pathogenic pathways have been proposed, including dysfunction of the retinal pigment epithelium, inflammation, and oxidative stress. The identification of AMD susceptibility genes encoding complement factors and the presence of complement and other inflammatory mediators in drusen, the hallmark deposits of AMD, support the concept that local inflammation and immune-mediated processes play a key role in AMD pathogenesis that may be accelerated through systemic immune activation. In this regard, increased levels of circulating C-reactive protein (CRP) have been associated with higher risk of AMD. Besides being a risk marker for AMD, CRP may also play a role in the progression of the disease as it has been identified in drusen, and we have recently found that its monomeric form (mCRP) induces blood retinal barrier disruption in vitro. In this review, we will address recent evidence that links CRP and AMD pathogenesis, which may open new therapeutic opportunities to prevent the progression of AMD.
Dipòsit Digital de Documents de la UAB
Publicación Artículo de revisión (ReviewArticle)

Epigenetic Modifications Associated to Neuroinflammation and Neuropathic Pain After Neural Trauma

  • Penas Pérez, Clara|||0000-0003-0554-3832
  • Navarro, X. (Xavier)|||0000-0001-9849-902X
Accumulating evidence suggests that epigenetic alterations lie behind the induction and maintenance of neuropathic pain. Neuropathic pain is usually a chronic condition caused by a lesion, or pathological change, within the nervous system. Neuropathic pain appears frequently after nerve and spinal cord injuries or diseases, producing a debilitation of the patient and a decrease of the quality of life. At the cellular level, neuropathic pain is the result of neuronal plasticity shaped by an increase in the sensitivity and excitability of sensory neurons of the central and peripheral nervous system. One of the mechanisms thought to contribute to hyperexcitability and therefore to the ontogeny of neuropathic pain is the altered expression, trafficking, and functioning of receptors and ion channels expressed by primary sensory neurons. Besides, neuronal and glial cells, such as microglia and astrocytes, together with blood borne macrophages, play a critical role in the induction and maintenance of neuropathic pain by releasing powerful neuromodulators such as pro-inflammatory cytokines and chemokines, which enhance neuronal excitability. Altered gene expression of neuronal receptors, ion channels, and pro-inflammatory cytokines and chemokines, have been associated to epigenetic adaptations of the injured tissue. Within this review, we discuss the involvement of these epigenetic changes, including histone modifications, DNA methylation, non-coding RNAs, and alteration of chromatin modifiers, that have been shown to trigger modification of nociception after neural lesions. In particular, the function on these processes of EZH2, JMJD3, MeCP2, several histone deacetylases (HDACs) and histone acetyl transferases (HATs), G9a, DNMT, REST and diverse non-coding RNAs, are described. Despite the effort on developing new therapies, current treatments have only produced limited relief of this pain in a portion of patients. Thus, the present review aims to contribute to find novel targets for chronic neuropathic pain treatment.
Dipòsit Digital de Documents de la UAB
Publicación Artículo de revisión (ReviewArticle)

Genetic kidney diseases as an underrecognized cause of chronic kidney disease, the key role of international registry reports

  • Torra Balcells, Roser|||0000-0001-8714-2332
  • Furlano, Monica|||0000-0003-1025-3901
  • Ortiz, Alberto|||0000-0002-9805-9523
  • Ars, Elisabet|||0000-0002-4118-4358
Inherited kidney diseases (IKDs) are among the leading causes of early-onset chronic kidney disease (CKD) and are responsible for at least 10-15% of cases of kidney replacement therapy (KRT) in adults. Paediatric nephrologists are very aware of the high prevalence of IKDs among their patients, but this is not the case for adult nephrologists. Recent publications have demonstrated that monogenic diseases account for a significant percentage of adult cases of CKD. A substantial number of these patients have received a non-specific/incorrect diagnosis or a diagnosis of CKD of unknown aetiology, which precludes correct treatment, follow-up and genetic counselling. There are a number of reasons why genetic kidney diseases are difficult to diagnose in adulthood: (i) adult nephrologists, in general, are not knowledgeable about IKDs; (ii) existence of atypical phenotypes; (iii) genetic testing is not universally available; (iv) family history is not always available or may be negative; (v) lack of knowledge of various genotype-phenotype relationships and (vi) conflicting interpretation of the pathogenicity of many sequence variants. Registries can contribute to visualize the burden of IKDs by regularly grouping all IKDs in their annual reports, as is done for glomerulonephritis or interstitial diseases, rather than reporting only cystic disease and hiding other IKDs under labels such as 'miscellaneous' or 'other'. Any effort to reduce the percentage of patients needing KRT with a diagnosis of 'nephropathy of unknown etiology' or an unspecific/incorrect diagnosis should be encouraged as a step towards precision nephrology. Genetic testing may be of value in this context but should not be used indiscriminately, but rather on the basis of a deep knowledge of IKDs.
Dipòsit Digital de Documents de la UAB
Publicación Artículo de revisión (ReviewArticle)

Recommendations of the Spanish Antibiogram Committee (COESANT) for selecting antimicrobial agents and concentrations for in vitro susceptibility studies using automated systems, Recomendaciones del Comité Español del Antibiograma (COESANT) para la selección de antimicrobianos y sus concentraciones en el estudio in vitro de la sensibilidad con métodos automáticos

  • Cantón, Rafael|||0000-0003-1675-3173
  • Oliver, Antonio|||0000-0001-9327-1894
  • Alós, Juan Ignacio
  • Benito, Natividad|||0000-0001-6410-013X
  • Bou, German|||0000-0001-8837-0062
  • Campos, José
  • Calvo, Jorge
  • Canut-Blasco, Andrés
  • Castillo, Javier
  • Cercenado, Emilia|||0000-0002-5279-3773
  • Domínguez, Maria Ángeles
  • Fernández-Cuenca, Felipe
  • Guinea, Jesús
  • Larrosa, María Nieves|||0000-0001-8808-0233
  • Liñares, Josefina
  • López-Cerero, Lorena
  • López-Navas, Antonio
  • Marco, Francesc|||0000-0002-1863-6379
  • Mirelis, Beatriz
  • Moreno-Romo, Miguel Ángel
  • Morosini, María Isabel
  • Navarro Risueño, Ferran|||0000-0002-4302-2838
  • Oteo-Iglesias, Jesús|||0000-0003-3327-8263
  • Pascual Leone, Álvaro|||0000-0001-8975-0382
  • Pérez Trallero, Emilio
  • Pérez-Vázquez, María
  • Soriano Viladomiu, Alex|||0000-0002-9374-0811
  • Torres, Carmen
  • Vila Estapé, Jordi|||0000-0002-8025-3926
  • Martínez-Martínez, Luis
Automated antimicrobial susceptibility testing devices are widely implemented in clinical microbiology laboratories in Spain, mainly using EUCAST (European Committee on Antimicrobial Susceptibility Testing) breakpoints. In 2007, a group of experts published recommendations for including antimicrobial agents and selecting concentrations in these systems. Under the patronage of the Spanish Antibiogram Committee (Comité Español del Antibiograma, COESANT) and the Study Group on Mechanisms of Action and Resistance to Antimicrobial Agents (GEMARA) from the Spanish Society of Infectious Diseases and Clinical Microbiology (SEIMC), and aligned with the Spanish National Plan against Antimicrobial Resistance (PRAN), a group of experts have updated this document. The main modifications from the previous version comprise the inclusion of new antimicrobial agents, adaptation of the ranges of concentrations to cover the EUCAST breakpoints and epidemiological cut-off values (ECOFFs), and the inference of new resistance mechanisms. This proposal should be considered by different manufacturers and users when designing new panels or cards. In addition, recommendations for selective reporting are also included. With this approach, the implementation of EUCAST breakpoints will be easier, increasing the quality of antimicrobial susceptibility testing data and their microbiological interpretation. It will also benefit epidemiological surveillance studies as well as the clinical use of antimicrobials aligned with antimicrobial stewardship programs., Los sistemas automáticos utilizados en el estudio de la sensibilidad a los antimicrobianos están introducidos en la mayoría de los laboratorios de Microbiología Clínica en España, utilizando principalmente los puntos de corte del European Committee on Antimicrobial Susceptibility Testing (EUCAST). En 2007, un grupo de expertos publicó unas recomendaciones para incluir antimicrobianos y seleccionar concentraciones en estos sistemas. Bajo el auspicio del Comité Español del Antibiograma (COESANT) y del Grupo de Estudio de los Mecanismos de Acción y Resistencia a los Antimicrobianos (GEMARA) de la Sociedad Española de Enfermedades Infecciosas y Microbiología Clínica (SEIMC) y alineado con el Plan Nacional frente a la Resistencia a los Antibióticos (PRAN), un grupo de expertos ha actualizado dicho documento. Las principales modificaciones realizadas sobre la versión anterior comprenden la inclusión de nuevos agentes antimicrobianos, la adaptación de los rangos de concentraciones para cubrir los puntos de corte clínicos y los puntos de corte epidemiológicos (ECOFF) definidos por el EUCAST, y para la inferencia de nuevos mecanismos de resistencia. Esta propuesta debería ser considerada por los diferentes fabricantes y los usuarios cuando se diseñen nuevos paneles o tarjetas. Además, se incluyen recomendaciones para realizar informes selectivos. Con este enfoque, la implementación de los puntos de corte del EUCAST será más fácil, aumentando la calidad de los datos del antibiograma y su interpretación microbiológica. También será de utilidad para los estudios de vigilancia epidemiológica, así como para el uso clínico de los antimicrobianos, de acuerdo con los programas de optimización de uso de antimicrobianos (PROA).
Dipòsit Digital de Documents de la UAB
Publicación Artículo de revisión (ReviewArticle)

Effects of Polyphenol Intake on Metabolic Syndrome, Current Evidences from Human Trials

  • Chiva-Blanch, Gemma|||0000-0001-6093-0160
  • Badimon, Lina|||0000-0002-9162-2459
Metabolic syndrome (MetS) is a cluster of cardiovascular risk factors which severely increases the risk of type II diabetes and cardiovascular disease. Several epidemiological studies have observed a negative association between polyphenol intake and MetS rates. Nevertheless, there are relatively small numbers of interventional studies evidencing this association. This review is focused on human interventional trials with polyphenols as polyphenol-rich foods and dietary patterns rich in polyphenols in patients with MetS. Current evidence suggests that polyphenol intake has the potential to alleviate MetS components by decreasing body weight, blood pressure, and blood glucose and by improving lipid metabolism. Therefore, high intake of polyphenol-rich foods such as nuts, fruits, vegetables, seasoning with aromatic plants, spices, and virgin olive oil may be the cornerstone of a healthy diet preventing the development and progression of MetS, although there is no polyphenol or polyphenol-rich food able to influence all MetS features. However, inconsistent results have been found in different trials, and more long-term randomized trials are warranted to develop public health strategies to decrease MetS rates.
Dipòsit Digital de Documents de la UAB
Publicación Artículo de revisión (ReviewArticle)

Peripheral immune aberrations in fibromyalgia, a systematic review, meta-analysis and meta-regression

  • Andrés Rodríguez, Laura|||0000-0001-5133-9811
  • Borràs, Xavier|||0000-0003-3972-1385
  • Feliu-Soler, Albert|||0000-0003-2810-7670
  • Pérez-Aranda, Adrián|||0000-0002-1602-3413
  • Angarita-Osorio, Natalia|||0000-0001-8925-2754
  • Moreno-Peral, Patricia|||0000-0003-4130-9090
  • Montero-Marín, Jesús|||0000-0001-5677-1662
  • Garcia-Campayo, Javier|||0000-0002-3797-4218
  • Carvalho, André F.
  • Maes, Michael|||0000-0002-2012-871X
  • Luciano, Juan Vicente|||0000-0003-0750-1599
The objective was to identify immune alterations in patients with fibromyalgia syndrome (FMS) compared to healthy controls (HC) using meta-analysis and meta-regression. Six electronic databases were searched for suitable original articles investigating immune biomarkers in FMS in comparison to HC. We extracted outcomes and variables of interest, such as mean and SD of peripheral blood immune biomarkers, age or sex. A random-effects model with restricted maximum-likelihood estimator was used to compute effect sizes (standardized mean difference and 95% CI, Hedges' g) and meta-analysis, group meta-analysis and meta-regressions were conducted. Forty-three papers were included in this systematic review, of which 29 were suitable for meta-analysis. Interleukin (IL)-6 (g = 0.36 (0.09-0.63); I2 = 85.94; p = 0.01), IL-4 (g = 0.50 (0.03-0.98); I2 = 81.87; p = 0.04), and IL-17A (g = 0.53 (0.00-1.06); I2 = 87.15; p = 0.05), were significantly higher in FMS compared to HC while also combinations of cytokines into relevant phenotypes were significantly upregulated including M1 macrophage (g = 0.23 (0.03-0.43); I2 = 77.62; p = 0.02), and immune-regulatory (g = 0.40 (0.09-0.72); I2 = 84.81; p = 0.01) phenotypes. Heterogeneity levels were very high and subgroup and meta-regression analyses showed that many covariates explained part of the heterogeneity including medication washout, sex, time of blood sampling and exclusion of patients with major depressive disorder. In conclusion, FMS is accompanied by a disbalance between upregulated pro-inflammatory (M1 and Th-17) and immune-regulatory cytokines although effect sizes are small-to-moderate. Based on our results we provide specific methodological suggestions for future research, which should assess Th-1, Th-17, chemokines, and Th-2 phenotypes while controlling for possible confounding variables specified in this study.
Dipòsit Digital de Documents de la UAB
Publicación Artículo de revisión (ReviewArticle)

Treatment of alcohol use disorder in patients with alcohol-associated liver disease, Innovative approaches and a call to action

  • Haque, Lamia Y.|||0000-0002-6650-0978
  • Zuluaga Blanco, Yenny Paola|||0000-0002-0247-0351
  • Muga, Roberto|||0000-0001-6301-431X
  • Fuster, Daniel|||0000-0003-1262-5860
Alcohol-associated liver disease is currently the leading cause of liver transplantation and liver deaths both in Europe and the United States. Efficacious treatments exist for alcohol use disorder, but they are seldomly prescribed for patients who need them. Besides, the presence of liver cirrhosis can complicate pharmacological treatment choices. In this review, we discuss established and innovative treatment strategies to treat unhealthy alcohol use in patients with alcohol-associated liver disease. We also describe the experience of our own institutions, Hospital Universitari Germans Trias i Pujol in Badalona (Spain) and Yale-New Haven Health and Yale Medicine (Connecticut. United States of America).